Immuno-Biological Laboratories Co., Ltd. (TYO:4570)
Japan · Delayed Price · Currency is JPY 1,170.00
+14.00 (1.21%)
Oct 6, 2026, 3:30 PM JST
TYO:4570 Ratios and Metrics
Market cap in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 5, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 10,897 | 12,499 | 4,470 | 4,927 | 3,791 | 3,046 | |
Market Cap Growth | 151.07% | 179.58% | -9.26% | 29.98% | 24.46% | -40.76% |
Enterprise Value | 10,161 | 11,789 | 3,907 | 4,534 | 3,633 | 2,855 |
Last Close Price | 1170.00 | 1342.00 | 477.95 | 526.74 | 405.26 | 325.60 |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 5, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 29.53 | 37.99 | 17.95 | 26.49 | - | - |
PS Ratio | 10.10 | 12.45 | 4.61 | 6.04 | 4.77 | 4.71 |
PB Ratio | 5.77 | 6.78 | 2.95 | 3.90 | 3.52 | 2.23 |
P/TBV Ratio | 5.78 | 6.79 | 2.96 | 3.90 | 3.52 | 2.23 |
P/FCF Ratio | 40.66 | 46.64 | 36.05 | 42.11 | 145.79 | - |
P/OCF Ratio | 36.20 | 41.52 | 24.43 | 37.04 | 145.79 | - |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 5, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 9.42 | 11.74 | 4.03 | 5.56 | 4.58 | 4.41 |
EV/EBITDA Ratio | 27.93 | 39.43 | 17.44 | 40.48 | - | - |
EV/EBIT Ratio | 29.45 | 41.95 | 18.70 | 41.22 | 69.86 | - |
EV/FCF Ratio | 37.91 | 43.99 | 31.51 | 38.75 | 139.72 | - |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 5, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 0.09 | 0.10 | 0.14 | 0.19 | 0.22 | 0.17 |
Debt / EBITDA Ratio | 0.47 | 0.59 | 0.91 | 2.10 | - | - |
Debt / FCF Ratio | - | 0.66 | 1.65 | 2.01 | 9.00 | - |
Net Debt / Equity Ratio | -0.39 | -0.44 | -0.41 | -0.39 | -0.35 | -0.20 |
Net Debt / EBITDA Ratio | -2.02 | -2.72 | -2.77 | -4.45 | - | - |
Net Debt / FCF Ratio | - | -3.03 | -5.01 | -4.26 | -14.61 | 2.96 |
Asset Turnover | 0.52 | 0.50 | 0.56 | 0.54 | 0.51 | 0.37 |
Inventory Turnover | 0.79 | 0.86 | 1.05 | 0.94 | 0.83 | 0.85 |
Quick Ratio | 3.74 | 4.23 | 3.76 | 3.60 | 3.30 | 2.99 |
Current Ratio | 5.18 | 5.69 | 4.95 | 4.91 | 4.62 | 4.95 |
Return on Equity (ROE) | 21.32% | 19.60% | 17.92% | 15.88% | -23.63% | -17.22% |
Return on Assets (ROA) | 10.41% | 8.78% | 7.54% | 4.50% | 2.07% | -4.30% |
Return on Capital Employed (ROCE) | 17.90% | 15.00% | 13.40% | 8.10% | 4.40% | -8.30% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Oct '26 Oct 5, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | 3.39% | 2.63% | 5.57% | 3.77% | -7.62% | -8.47% |
FCF Yield | 2.46% | 2.14% | 2.77% | 2.38% | 0.69% | -3.05% |
Dividend Yield | 0.64% | 0.45% | - | - | - | - |
Total Shareholder Return | 0.64% | 0.45% | - | - | - | - |